Sugi Predict

Sugi Predict / Compounds / SCHEMBL58303

SCHEMBL58303

SCHEMBL58303

O=C=Nc1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ HTR3E A5X5Y0 1/20 0.56
▸ HTR3B O95264 1/20 0.56
▸ HTR3A P46098 1/20 0.56
▸ HTR3D Q70Z44 1/20 0.56
▸ HTR3C Q8WXA8 1/20 0.56
▸ KDR P35968 1/20 0.44
▸ KMT2A Q03164 1/20 0.43
▸ CYP3A4 P08684 2/20 0.41
▸ TRPA1 O75762 1/20 0.41
▸ IDO1 P14902 2/20 0.40
▸ PYCR1 P32322 1/20 0.40
▸ NOTUM Q6P988 5/20 0.40
▸ PDK1 Q15118 1/20 0.40
▸ NPFFR2 Q9Y5X5 3/20 0.39
▸ NPFFR1 Q9GZQ6 2/20 0.39
▸ TSHR P16473 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29397209 1.00 MAPK1 (0.61) MAPK1TDP1HTR3EHTR3BHTR3A
Tetrahydrofuran SCHEMBL28279164 0.88 MAPK1 (0.49) MAPK1TDP1HTR3EHTR3BHTR3A
SCHEMBL8593598 0.87 MAPK1 (0.47) MAPK1TDP1HTR3EHTR3BHTR3A
SCHEMBL856525 0.86 MAPK1 (0.61) MAPK1TDP1HTR3EHTR3BHTR3A
SCHEMBL10788009 0.84 MAPK1 (0.63) MAPK1TDP1HTR3EHTR3BHTR3A
SCHEMBL1555041 0.83 MAPK1 (0.47) MAPK1TDP1HTR3EHTR3BHTR3A
SCHEMBL881834 0.82 HTR3E (0.56) MAPK1TDP1HTR3EHTR3BHTR3A
SCHEMBL3837474 0.82 MAPK1 (0.42) MAPK1TDP1HTR3EHTR3BHTR3A
SCHEMBL7177146 0.81 MAPK1 (0.46) MAPK1TDP1HTR3EHTR3BHTR3A
SCHEMBL29648906 0.80 MAPK1 (0.44) MAPK1TDP1HTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4674846-A1 UREA MOTIF CONTAINING COMPOUNDS AS ANTIBACTERIAL DRUGS AGAINST MULTIRESISTANT MYCOBACTERIA Technische Universität München (DE) 2026-01-07 — — EP claimed
CN-119492845-A Analysis method of 4-chloro-3-trifluoromethyl isocyanate related substances 南京正大天晴制药有限公司 2025-02-21 — — CN claimed
CN-119241427-A Method for comprehensively and efficiently synthesizing anticancer drug regorafenib 董帅圻 2025-01-03 — — CN claimed
CN-115108977-B Regorafenib preparation method of nylon 南京正大天晴制药有限公司 2024-11-29 — — CN claimed
CN-118814496-A Preparation method and application of wear-resistant organic silicon leather 匠指(广东)有机硅材料有限公司 2024-10-22 — — CN claimed
CN-118108667-A Preparation method of regorafenib 南京法恩化学有限公司 2024-05-31 — — CN claimed
CN-114315710-B Method for preparing or purifying regorafenib 江苏豪森药业集团有限公司 2024-04-26 — — CN claimed
CN-114349707-B N-substituted urea compound and preparation method and application thereof 中国医学科学院医药生物技术研究所 2024-01-09 — — CN claimed
CN-113466395-B Method for detecting content of 4-chloro-3-trifluoromethyl isocyanate phenyl in regorafenib and intermediate drug 杭州微源检测技术有限公司 2023-11-21 — — CN claimed
US-11674140-B2 Compositions and methods for treating facioscapulohumeral dystrophy THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-06-13 — — US claimed
EP-2089363-A1 POLYMORPH II OF 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}AMINO)-3-FLUOROPHENOXY]N-METHYLPYRIDINE-2-CARBOXAMIDE Bayer Schering Pharma Aktiengesellschaft (DE) 2009-08-19 — — EP claimed
US-20080262236-A1 Process for the Preparation of 4-Carbonyl)Amino]Phenoxy}-N-Methylpyridine-2-Carboxamide BAYER HEALTHCARE AG (DE) 2008-10-23 — — US claimed
WO-2008058644-A1 POLYMORPH II OF 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-05-22 — — WO claimed
CN-101052619-A Process for the preparation of 4- { 4- [ ({ [ 4-chloro-3- (trifluoromethyl) phenyl ] amino } carbonyl) amino ] phenoxy } -N-methylpyridine-2-carboxamide BAYER HEALTHCARE AG (DE) 2007-10-10 — — CN claimed
EP-1797037-A1 PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENYOXY}N-METHYLPYRIDINE-2-CARBOXAMIDE Bayer HealthCare AG (DE) 2007-06-20 — — EP claimed
WO-2006034796-A1 PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE BAYER HEALTHCARE AG (DE) 2006-04-06 — — WO claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 — — EP claimed
EP-0129214-B1 METHOD FOR THE PREPARATION OF BENZENAMINES OCCIDENTAL CHEMICAL CORPORATION (US) 1986-10-29 — — EP claimed
EP-0129214-A1 Method for the preparation of benzenamines OCCIDENTAL CHEMICAL CORPORATION (US) 1984-12-27 — — EP claimed
US-4481370-A REACTING HYDROGEN FLUORIDE WITH A PHENYL CARBAMIC FLUORIDE OCCIDENTAL CHEMICAL CORPORATION (US) 1984-11-06 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262236-A1 Process for the Preparation of 4-Carbonyl)Amino]Phenoxy}-N-Methylpyridine-2-Carboxamide PNMT, TET2, TET3 MAPK1 2048/4885TDP1 1943/4885HTR3E 621/4885
US-11674140-B2 Compositions and methods for treating facioscapulohumeral dystrophy MYOF, MTPN, CPT1B MAPK1 4658/4885TDP1 563/4885HTR3E 4639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.